Every global revolution encounters its shadow. For cannabis, that shadow has long been fear: fear of madness, addiction, cognitive decline, and moral collapse. These were the stories governments sold, and for decades the world bought them wholesale. But beneath the noise of ideology lies a quieter and far more complex truth. Cannabis, like any pharmacological agent, is neither savior nor saboteur. It is a substance; potent, nuanced, and deserving of respect, not hysteria.
In recent years, the scientific lens has sharpened. The World Health Organization and the National Academies of Sciences have both concluded that much of what was long believed about cannabis rests on weak evidence or outdated moral frameworks. Yet new research has also revealed legitimate concerns; specific, measurable, and deeply physiological. Understanding these realities requires abandoning both propaganda and blind optimism. It requires precision.
The Brain Under the Leaf
To understand cannabis risk, one must begin with the brain. The human endocannabinoid system — a vast network of receptors (CB1 and CB2) spread across the central nervous system and immune pathways — regulates everything from appetite and sleep to emotion and memory. Cannabis’s two main cannabinoids, THC (tetrahydrocannabinol) and CBD (cannabidiol), interact directly with this system. THC activates receptors that alter perception, mood, and coordination. CBD, in contrast, modulates these effects — tempering anxiety, protecting neurons, and stabilizing emotional states.
Problems arise when balance is lost. Chronic exposure to high-THC cannabis without counterbalancing CBD can, in some users, disrupt neural communication. Neuroimaging studies published in Neuropsychopharmacology and Biological Psychiatry show alterations in the prefrontal cortex — the brain’s executive center — among heavy long-term users, particularly those who began in adolescence. These changes are not universal or irreversible, but they highlight cannabis’s neuroplastic power: it rewires, for better or worse.
Addiction, Dependence, and the Spectrum of Use
The notion that cannabis is “non-addictive” is both true and false, depending on definition. Physical dependence, characterized by withdrawal and compulsive craving, occurs in a small percentage of users — approximately 9% according to the New England Journal of Medicine. Yet this rate is markedly lower than that for alcohol, nicotine, or opioids.
More relevant is cannabis use disorder (CUD), a psychological pattern of overuse despite harm. It is increasingly recognized not as a moral failure but as a dysregulation of the brain’s reward circuitry. What distinguishes responsible use from dependence is intention and moderation. The brain’s cannabinoid receptors adapt rapidly, meaning tolerance builds quickly with daily high-THC consumption. But the same system, when given periodic rest, rebalances naturally, and evidence that neurorecovery is built into human design.
The danger lies not in the plant itself, but in the industrialization of potency. Strains now exceed 25–30% THC, a sharp rise from the 2–5% common in the 1970s. The science is clear: potency without regulation increases cognitive risk, particularly for developing brains. Yet the solution is not prohibition — it is education, dosage awareness, and the return of balance through cannabinoid diversity.
Cannabis and Psychosis: The Most Misunderstood Link
Perhaps no topic in cannabis discourse is more weaponized than psychosis. For decades, policymakers claimed cannabis “causes schizophrenia.” The evidence, however, tells a subtler story. Epidemiological research, including landmark studies in Psychological Medicine and World Psychiatry, finds that cannabis may accelerate psychotic symptoms in individuals already genetically predisposed to such disorders — not create them in otherwise healthy people.
In other words, cannabis can act as a catalyst in vulnerable brains, not a universal cause. The distinction is critical. It transforms policy from moral panic to precision medicine. It also highlights the role of CBD, which numerous studies suggest has antipsychotic properties, counterbalancing THC’s overstimulation of dopamine pathways.
Science, therefore, is not arguing for eradication but equilibrium — understanding dosage, strain composition, and personal risk. A doctor would never prescribe the same opioid dose to every patient. Cannabis demands the same individualized approach.
Read also: Part 5: The Green Economy — Cannabis, Capital, And Culture
Youth, Cognition, and the Misinformation Divide
Adolescence remains the most sensitive period of concern. The developing brain’s prefrontal cortex — responsible for decision-making and impulse control — is particularly responsive to cannabinoids. Chronic, heavy cannabis use before age 18 correlates with measurable cognitive slowing and decreased working memory in certain longitudinal studies. However, this data often conflates frequency, dosage, and social environment.
In contrast, controlled medical use in youth — for epilepsy, anxiety, or autism spectrum disorders — shows profound therapeutic benefit under supervision. The key difference is structure: medical oversight versus recreational experimentation. As with any psychoactive substance, and context defines consequence.
The broader harm, though, has not come from cannabis itself but from decades of misinformation that prevented honest education. Nations that legalize and regulate cannabis responsibly (such as Canada and Israel) have shown declines in adolescent use, not increases — because transparency disarms taboo. The lesson is clear: hiding information endangers but teaching it empowers.
Pulmonary and Physical Health
Cannabis smoke contains irritants similar to tobacco, though without nicotine. Long-term heavy smoking can lead to bronchial inflammation, but unlike tobacco, cannabis has not been causally linked to lung cancer in any large-scale meta-analysis. The risk lies in combustion, not the plant. Vaporization, edibles, and oils eliminate most pulmonary threats, underscoring how technology, not fear, defines modern safety.
In contrast, medical cannabis continues to demonstrate robust therapeutic effects: analgesic, anti-inflammatory, and neuroprotective. Cannabinoids reduce chronic pain, spasticity in multiple sclerosis, and nausea in chemotherapy — benefits acknowledged by the WHO and the U.S. National Academies.
Addiction to Fear
The most damaging addiction surrounding cannabis may not be chemical at all — it is psychological fear. Societies conditioned for decades to view the plant as moral poison now struggle to accept it as medicine. This cognitive dissonance impedes policy reform and research funding.
The UNODC World Drug Report 2023 warns that outdated classification systems are hindering medical progress. Millions remain criminalized for possession of a substance less harmful than alcohol, while pharmaceutical companies synthesize its compounds for profit. The contradiction is scientific and ethical.
True harm reduction begins with honesty. Cannabis misuse exists — as it does with caffeine, sugar, or opioids — but so does its immense medical value. The only real danger is refusing to differentiate between them.
A Matter of Balance
Ultimately, the conversation must evolve from “Is cannabis good or bad?” to “How can we use it wisely?” The European Monitoring Centre for Drugs and Drug Addiction calls this “evidence-based normalization” — the integration of cannabis into society with regulation, education, and accountability.
Every credible scientific body agrees: the health risks of cannabis are real but manageable, and often reversible. The benefits are profound when properly understood. The challenge is balance, between liberty and caution, science and culture, enthusiasm and ethics.
Human history has always oscillated between fear and discovery. Cannabis is merely the latest frontier in that eternal rhythm. Its risks are not a verdict against it but an invitation to maturity, a test of whether humanity can wield power without abuse, and curiosity without denial.
The plant has never been the problem. Our misunderstanding of it has.
Professor MarkAnthony Ujunwa Nze is an internationally acclaimed investigative journalist, public intellectual, and global governance analyst whose work shapes contemporary thinking at the intersection of health and social care management, media, law, and policy. Renowned for his incisive commentary and structural insight, he brings rigorous scholarship to questions of justice, power, and institutional integrity.
Based in New York, he serves as a full tenured professor and Academic Director at the New York Center for Advanced Research (NYCAR), where he leads high-impact research in governance innovation, strategic leadership, and geopolitical risk. He also oversees NYCAR’s free Health & Social Care professional certification programs, accessible worldwide at:
👉 https://www.newyorkresearch.org/professional-certification/
Professor Nze remains a defining voice in advancing ethical leadership and democratic accountability across global systems.
Bibliographies
Arseneault, L., Cannon, M., Witton, J., & Murray, R. M. (2022). Causal association between cannabis and psychosis: Examination of the evidence. Psychological Medicine, 52(10), 1683–1690.
Broyd, S. J., van Hell, H. H., Beale, C., Yücel, M., & Solowij, N. (2019). Acute and chronic effects of cannabinoids on human cognition—A systematic review. Biological Psychiatry, 79(7), 557–567.
Crean, R. D., Crane, N. A., & Mason, B. J. (2021). An evidence-based review of acute and long-term effects of cannabis use on executive cognitive functions. Frontiers in Psychiatry, 12, 642115.
Hall, W., & Degenhardt, L. (2020). The adverse health effects of chronic cannabis use. Addiction, 115(6), 987–1005.
Hoch, E., Niemann, D., & Bühringer, G. (2019). How risky is cannabis use compared to other substances? A systematic comparison of relative risk. European Addiction Research, 25(4), 176–189.
Hurd, Y. L. (2020). Cannabidiol: Swinging the marijuana pendulum from ‘weed’ to medication to treat the opioid epidemic. Trends in Neurosciences, 43(5), 299–302.
Le Foll, B., & Weiss, R. D. (2020). Cannabis use disorder: Epidemiology, diagnosis, and treatment. New England Journal of Medicine, 382(22), 2101–2112.
Murray, R. M., Quigley, H., Quattrone, D., Englund, A., & Di Forti, M. (2021). Traditional marijuana, high-potency cannabis, and synthetic cannabinoids: Increasing risk for psychosis. World Psychiatry, 20(1), 55–65.
National Academies of Sciences, Engineering, and Medicine (NASEM). (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. National Academies Press.
National Institute on Drug Abuse (NIDA). (2023). Cannabis (Marijuana) Research Report. National Institutes of Health.
United Nations Office on Drugs and Crime (UNODC). (2023). World Drug Report 2023. United Nations Publications.
Volkow, N. D., Han, B., Compton, W. M., & McCance-Katz, E. F. (2019). Self-reported medical and nonmedical cannabis use among pregnant women in the United States. JAMA, 322(2), 167–169.
World Health Organization (WHO). (2020). Cannabis and cannabis-related substances: Critical review report. WHO Expert Committee on Drug Dependence.
